Statera Biopharma, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced that it entered into a securities purchase agreement with a certain institutional investor to purchase approximately $2.0 million worth of its common stock and warrants in a registered direct offering.
February 6, 2022
· 5 min read